Moreover, 225Ac-NM600 promoted a more active CD8+ T cell repertoire with increased expression of activation and proliferation markers such as CD44+, CD69+, and Ki67+ on CD8+ T cells, suggesting the induction of an immunogenic TME by 225Ac-NM600, which could be responsible for the anti-tumor response. Here, CD8A is linked to neoplasm.